REPLIGEN CORP
RGENNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $738.3M | $634.4M | $632.4M | $801.5M | $670.5M | $76.1M |
| Operating income | $55.2M | −$35.1M | $47.7M | $224.7M | $167.2M | $69.8M |
| Net income | $48.9M | −$25.5M | $35.6M | $186.0M | $128.3M | $9.8M |
| Total assets | $2.95B | $2.83B | $2.83B | $2.52B | $2.36B | $1.90B |
| Total liabilities | $843.6M | $856.9M | $866.3M | $614.0M | $608.3M | $373.7M |
| Equity | $2.11B | $1.97B | $1.96B | $1.91B | $1.75B | $1.53B |
| EPS (diluted) | $0.86 | $-0.46 | $0.63 | $3.24 | $2.24 | $0.18 |
| Shares out. | 56.1M | 55.8M | 55.6M | 55.3M | 54.8M | 52.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 7.5%
- Net margin
- 6.6%
- Return on equity
- 2.3%
- Return on assets
- 1.7%
- Return on capital (ROCE)
- 2.0%
- Liabilities / assets
- 28.6%
- Debt / equity
- 0.40×
- Book value / share
- $37.51
- Revenue growth (YoY)
- 16.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 5.48safe
- Accruals / assets
- −2.3%clean
- Beneish M-Score
- -2.51normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 6 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 3, 2025
- NT 10-Qmissed a reporting deadline ↗Nov 12, 2024
- NT 10-Kmissed a reporting deadline ↗Mar 3, 2015
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Group IncPassive (13G)Mar 27, 2026
- Price T Rowe Associates Inc /Md/Passive (13G)Feb 17, 2026
- Roy T. Eddleman Living TrustPassive (13G)Feb 13, 2026
- Fmr LlcPassive (13G)Feb 5, 2026
- Blackrock, Inc.Passive (13G)Apr 24, 2025
- Eddleman Roy TPassive (13G)Feb 13, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Madaus Martin DDirector | May 14, 2026 | Grant | 995 | $0.00 |
| Konstantinov KonstantinDirector | May 14, 2026 | Grant | 995 | $0.00 |
| Eglinton Manner CarrieDirector | May 14, 2026 | Grant | 995 | $0.00 |
| Mhatre RohinDirector | May 14, 2026 | Grant | 995 | $0.00 |
| Pax MargaretDirector | May 14, 2026 | Grant | 995 | $0.00 |
| Muir Glenn PDirector | May 14, 2026 | Grant | 995 | $0.00 |
| Dawes Karen ADirector | May 14, 2026 | Grant | 995 | $0.00 |
| Barthelemy NicolasDirector | May 14, 2026 | Grant | 995 | $0.00 |
| Muir Glenn PDirector | May 7, 2026 | Option exercise | 2,434 | $38.76 |
| Douglass Brian RobbOfficer — CHIEF PRODUCT OFFICER | May 7, 2026 | Tax withholding | 334 | $126.43 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 5.7M | 3.9 | +3.5% |
| Apr 30, 2026 | 5.5M | 5.0 | +0.3% |
| Apr 15, 2026 | 5.5M | 7.0 | -1.3% |
| Mar 31, 2026 | 5.6M | 6.3 | +28.0% |
| Mar 13, 2026 | 4.3M | 4.7 | +8.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 15, 2026
- Results of operationsMay 5, 2026
- Results of operationsFeb 24, 2026
- Director / officer change · Regulation FD disclosureJan 6, 2026
- Results of operationsOct 28, 2025
- Director / officer changeSep 2, 2025
- Results of operationsJul 29, 2025
- Amended charter or bylaws · Shareholder voteMay 15, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.